☰Menu

Survival Rate for Advanced-stage Prostate Cancer Patients with Surgery

Author: Mayo Clinic
Published: 15 May 2011 - Updated: 9 Nov 2023
Publication Details: Peer-Reviewed | Informative

Table of Contents:
Synopsis - Overview - Related Content

Synopsis

Long-term survival rates for patients with advanced prostate cancer suggest they can be good candidates for surgery.

Overview

Advanced-stage prostate cancer patients experience 20-year survival rates with surgery. Long-term survival rates for patients with advanced prostate cancer suggest they can be good candidates for surgery, Mayo Clinic researchers have found.

Their study found a 20-year survival rate for 80 percent of patients diagnosed with cancer that has potentially spread beyond the prostate, known as cT3 prostate cancer, and treated with radical prostatectomy, or surgery to remove the prostate gland. Previously, patients found to have cT3 prostate cancer were offered radiation or hormone treatment, but not radical prostatectomy.

The researchers presented their findings during the American Urological Association Annual Meeting in Washington.

"We are doing a much better job of identifying and expanding candidates for surgery, which results in better, longer outcomes for so many of our patients," says R. Jeffrey Karnes, M.D., of Mayo Clinic's Department of Urology. "We have confirmed that patients diagnosed with locally advanced prostate cancer can enjoy a long, cancer-free interval."

The 80 percent survival rate for cT3 diagnoses at 20 years compares to 90 percent for cT2, or cancer confined to the prostate.

This long-term follow-up of patients who underwent surgery between 1987 and 1997 is an important advance in understanding the quality outcomes for cT3 patients.

The study sample included patients diagnosed and operated on between 1987 and 1997. Ongoing research will examine contemporary data.

Other study investigators include Christopher Mitchell, M.D., Eric Umbreit, M.D., Rachel Carlson and Laureano Rangel, all of Mayo Clinic.


Attribution/Source(s): This peer-reviewed publication was selected for publishing by the editors of Disabled World (DW) due to its relevance to the disability community. Originally issued as a press release by Mayo Clinic and published on 15 May 2011. Last updated on 9 Nov 2023. This content may have been edited for style, clarity, or brevity.

Renaming Low-Risk Prostate Cancer May Save Lives Each Year

Relabeling Grade Group 1 prostate cancer as a precancerous condition could curb overtreatment, increase PSA screening and prevent deaths, a UCLA-led model finds. Published: 1 Jul 2026.

Two-Week Radiotherapy Matches Eight-Week Prostate Cancer Treatment

A decade-long phase 3 trial shows 2 week radiotherapy is as safe and effective as 8 week treatment for prostate cancer, with similar survival and side effects. Published: 5 May 2025.

PI-RADS Score Chart: Prostate MRI Cancer Assessment

PI-RADS is a standardized 1 to 5 scoring system that uses prostate mpMRI to assess the likelihood of clinically significant cancer and guide biopsies. Published: 27 Jan 2025.

Gleason Scores and Grade Groups in Prostate Cancer Explained

Learn how Gleason scores and Grade Groups 1 to 5 rate prostate cancer aggressiveness, why 3+4 differs from 4+3, and how the grade guides treatment choices. Published: 26 Jan 2025.

Share or cite this page:

<a href="https://www.disabled-world.com/health/cancer/prostate/advanced-stage.php">Survival Rate for Advanced-stage Prostate Cancer Patients with Surgery</a>: Long-term survival rates for patients with advanced prostate cancer suggest they can be good candidates for surgery.

While we aim to provide accurate, up-to-date information, our content is for general informational purposes only and is not a substitute for professional advice. Consult a qualified professional about your specific situation.

BACK TO TOP